Key Takeaways
- • HydRegen, an Oxford, UK and San Francisco-based biotechnology company, closed $8 million (£6 million) in the first close of its Series A financing, according to a Business Wire press release dated October 14, 2026.
- • Genoa Ventures led the round, with participation from Clean Growth Fund and First Imagine! Ventures, and additional support from Oxford Technology Management, Headington Holdings, Oxonian, Foxglove Capital and Rapid Innovation Group.
- • HydRegen claims its enzyme-based catalysts can make chemical manufacturing up to 40% more cost-effective while lowering carbon emissions, and that they drop into existing plant infrastructure without redesign.
- • Proceeds will fund expansion with existing pharmaceutical and specialty chemical customers and new adoption across chemicals, agrochemicals, materials and bulk chemicals.
Summary
HydRegen has closed $8 million (£6 million) in the first close of its Series A financing, the company announced in a Business Wire press release. Genoa Ventures led the round, with participation from Clean Growth Fund and First Imagine! Ventures. Oxford Technology Management, Headington Holdings, Oxonian, Foxglove Capital and Rapid Innovation Group also provided support.
The company positions its technology as an alternative to precious-metal catalysts used in hydrogenation, a step the company says is essential to 14 to 20% of processes in the trillion-dollar industrial chemicals market. Conventional precious-metal processes can be energy-intensive, difficult to optimize and increasingly challenging to run under tightening environmental and regulatory requirements. HydRegen produces a hydrogenase enzyme through fermentation and formulates it into proprietary catalyst platforms that the company says can perform hundreds of different hydrogenation reactions. According to the company, the catalysts can turn over millions of times and integrate as a drop-in replacement in existing equipment.
Holly Reeve, PhD, CEO and co-founder of HydRegen, said that asking manufacturers to abandon existing infrastructure would hinder adoption, and that the company's approach allows manufacturers to change the catalyst without changing the factory. Jenny Rooke, PhD, founder and managing director of Genoa Ventures, cited the company's science, economics, scale-up path, capital efficiency and demonstrated customer demand as reasons for the investment.
The funding will support higher-volume markets and additional applications, giving manufacturers more flexibility across molecules, feedstocks and processes. The company's headline claim of up to 40% cost savings is company-stated and has not been independently verified in the source material. HydRegen is headquartered in Oxford, UK, with a San Francisco presence, and more information is available at hydregenoxford.com.
The company positions its technology as an alternative to precious-metal catalysts used in hydrogenation, a step the company says is essential to 14 to 20% of processes in the trillion-dollar industrial chemicals market. Conventional precious-metal processes can be energy-intensive, difficult to optimize and increasingly challenging to run under tightening environmental and regulatory requirements. HydRegen produces a hydrogenase enzyme through fermentation and formulates it into proprietary catalyst platforms that the company says can perform hundreds of different hydrogenation reactions. According to the company, the catalysts can turn over millions of times and integrate as a drop-in replacement in existing equipment.
Holly Reeve, PhD, CEO and co-founder of HydRegen, said that asking manufacturers to abandon existing infrastructure would hinder adoption, and that the company's approach allows manufacturers to change the catalyst without changing the factory. Jenny Rooke, PhD, founder and managing director of Genoa Ventures, cited the company's science, economics, scale-up path, capital efficiency and demonstrated customer demand as reasons for the investment.
The funding will support higher-volume markets and additional applications, giving manufacturers more flexibility across molecules, feedstocks and processes. The company's headline claim of up to 40% cost savings is company-stated and has not been independently verified in the source material. HydRegen is headquartered in Oxford, UK, with a San Francisco presence, and more information is available at hydregenoxford.com.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.